Evidence map›Paper›PMID 33777408›Full record

ArticleParasitology open2019

Effects of diethylcarbamazine and ivermectin treatment on

Mary J Maclean, W Walter Lorenz, Michael T Dzimianski, Christopher Anna, Andrew R Moorhead, Barbara J Reaves, Adrian J Wolstenholme

Open access · hybridAbstract read
In one paragraph

Article in Parasitology open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mary J MacleanDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
W Walter LorenzInstitute for Bioinformatics, University of Georgia, Athens, GA 30602, USA.
Michael T DzimianskiDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Christopher AnnaPerthera Inc., McLean, VA 22102, USA.
Andrew R MoorheadDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Barbara J ReavesDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Adrian J WolstenholmeDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0001-7989-3929
University of Georgia · US

Funding

The antifilarial activity of ivermectin and diethylcarbamizineR01AI103140 · NIAID · UNIVERSITY OF GEORGIA · PI WOLSTENHOLME, ADRIAN J · 2014 to 2016
$1.1M
NIAID NIH HHS R01 AI103140
6 · The paper itself

Abstract

Lymphatic filariasis (LF) threatens nearly 20% of the world's population and has handicapped one-third of the 120 million people currently infected. Current control and elimination programs for LF rely on mass drug administration of albendazole plus diethylcarbamazine (DEC) or ivermectin. Only the mechanism of action of albendazole is well understood. To gain a better insight into antifilarial drug action

Indexed as

AlbendazoleBrugia malayidiethylcarbamazineivermectintranscriptome

Identifiers

PMID33777408
PMCPMC7994942
OpenAlexW2922464369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.